Australians suffering from melanoma and multiple sclerosis have new treatment options, with new and amended PBS listings.
🔸 Tafinlar® (dabrafenib) and Mekinist® (trametinib) will be extended to include subsidy for post-surgery treatment for patients who have Stages IIIB, IIIC and IIID melanoma.
🔸 Gilenya® (fingolimod) will be amended to include a new strength of this medicine for treatment of patients weighing 40kg or less, including paediatric patients.
🔸 Tysabri® (natalizumab) will be extended to remove the age restrictions for this medicine, to subsidise use in paediatric patients with relapsing remitting multiple sclerosis.
Since 2013, the Government has listed over 2,100 new or amended items on the PBS. This represents an average of around 30 listings per month – or one each day – at an overall cost of around $10.6 billion.